What does Context Therapeutics Inc. do?
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has…
What is Context Therapeutics Inc.'s P/E and P/B ratio?
Context Therapeutics Inc. has a P/E ratio of -0.5 and a P/B ratio of 0.57.
What is Context Therapeutics Inc.'s debt-to-equity ratio?
Context Therapeutics Inc. has a debt-to-equity ratio of 0.01.
How much does Context Therapeutics Inc. owe compared with what it owns?
Context Therapeutics Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Context Therapeutics Inc.'s Positivity rank?
Context Therapeutics Inc. is ranked #2,321 of 6,774 companies globally and #703 of 4,000 in United States on PositoAI, with a Positivity Score of 21,647.
Does Context Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Yes. Context Therapeutics Inc. has 1 active red flag (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 31 Jul 2026). It has no yellow flags.
Where can I read the latest news about Context Therapeutics Inc.?
Recent headlines about Context Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Context Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Context Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.